Copanlisib (Aliqopa)
General information
Class/mechanism: From NCI Drug Dictionary: A phosphoinositide 3-kinase (PI3K) inhibitor with potential antineoplastic activity. Copanlisib inhibits the activation of the PI3K signaling pathway, which may result in inhibition of tumor cell growth and survival in susceptible tumor cell populations.[1][2][3]
Route: PO
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, Medscape, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
History of changes in FDA indication - WITHDRAWN
- 2017-09-14: Granted accelerated approval for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies. (Based on CHRONOS-1)
- 2024-03-18: Accelerated approval for the treatment of adult patients with relapsed follicular lymphoma who have received at least two prior systemic therapies withdrawn.
Patient Information
Also known as
- Code name: BAY-80-6946
- Brand name: Aliqopa